IBDEI0Z5 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17457,1,1,0)
 ;;=1^V10.41
 ;;^UTILITY(U,$J,358.3,17457,1,8,0)
 ;;=8^Hx-Cervical Malignancy
 ;;^UTILITY(U,$J,358.3,17457,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,17458,0)
 ;;=V10.42^^111^1087^34
 ;;^UTILITY(U,$J,358.3,17458,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17458,1,1,0)
 ;;=1^V10.42
 ;;^UTILITY(U,$J,358.3,17458,1,8,0)
 ;;=8^Hx-Uterus Malignancy Nec
 ;;^UTILITY(U,$J,358.3,17458,2)
 ;;=^295220
 ;;^UTILITY(U,$J,358.3,17459,0)
 ;;=V10.43^^111^1087^11
 ;;^UTILITY(U,$J,358.3,17459,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17459,1,1,0)
 ;;=1^V10.43
 ;;^UTILITY(U,$J,358.3,17459,1,8,0)
 ;;=8^Hx Of Ovarian Malignancy
 ;;^UTILITY(U,$J,358.3,17459,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,17460,0)
 ;;=V10.44^^111^1087^18
 ;;^UTILITY(U,$J,358.3,17460,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17460,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,17460,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,17460,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,17461,0)
 ;;=V10.81^^111^1087^2
 ;;^UTILITY(U,$J,358.3,17461,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17461,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,17461,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,17461,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,17462,0)
 ;;=V10.82^^111^1087^25
 ;;^UTILITY(U,$J,358.3,17462,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17462,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,17462,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,17462,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,17463,0)
 ;;=V10.83^^111^1087^31
 ;;^UTILITY(U,$J,358.3,17463,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17463,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,17463,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,17463,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,17464,0)
 ;;=V10.84^^111^1087^6
 ;;^UTILITY(U,$J,358.3,17464,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17464,1,1,0)
 ;;=1^V10.84
 ;;^UTILITY(U,$J,358.3,17464,1,8,0)
 ;;=8^Hx Of Eye Malignancy
 ;;^UTILITY(U,$J,358.3,17464,2)
 ;;=^295242
 ;;^UTILITY(U,$J,358.3,17465,0)
 ;;=V10.85^^111^1087^3
 ;;^UTILITY(U,$J,358.3,17465,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17465,1,1,0)
 ;;=1^V10.85
 ;;^UTILITY(U,$J,358.3,17465,1,8,0)
 ;;=8^Hx Of Brain Malignancy
 ;;^UTILITY(U,$J,358.3,17465,2)
 ;;=^295243
 ;;^UTILITY(U,$J,358.3,17466,0)
 ;;=V10.86^^111^1087^26
 ;;^UTILITY(U,$J,358.3,17466,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17466,1,1,0)
 ;;=1^V10.86
 ;;^UTILITY(U,$J,358.3,17466,1,8,0)
 ;;=8^Hx-Malign Nerve Syst Nec
 ;;^UTILITY(U,$J,358.3,17466,2)
 ;;=^295244
 ;;^UTILITY(U,$J,358.3,17467,0)
 ;;=V10.88^^111^1087^16
 ;;^UTILITY(U,$J,358.3,17467,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17467,1,1,0)
 ;;=1^V10.88
 ;;^UTILITY(U,$J,358.3,17467,1,8,0)
 ;;=8^Hx-Endocrine Malign Nec
 ;;^UTILITY(U,$J,358.3,17467,2)
 ;;=^295246
 ;;^UTILITY(U,$J,358.3,17468,0)
 ;;=238.0^^111^1088^1
 ;;^UTILITY(U,$J,358.3,17468,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17468,1,1,0)
 ;;=1^238.0
 ;;^UTILITY(U,$J,358.3,17468,1,8,0)
 ;;=8^Bone and Articular Cartilage
 ;;^UTILITY(U,$J,358.3,17468,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,17469,0)
 ;;=238.1^^111^1088^3
 ;;^UTILITY(U,$J,358.3,17469,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17469,1,1,0)
 ;;=1^238.1
 ;;^UTILITY(U,$J,358.3,17469,1,8,0)
 ;;=8^Connective and Oth Soft Tissue
 ;;^UTILITY(U,$J,358.3,17469,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,17470,0)
 ;;=238.2^^111^1088^17
 ;;^UTILITY(U,$J,358.3,17470,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17470,1,1,0)
 ;;=1^238.2
 ;;^UTILITY(U,$J,358.3,17470,1,8,0)
 ;;=8^Skin
 ;;^UTILITY(U,$J,358.3,17470,2)
 ;;=^267777
